Viral Hepatitis Prevention Board (1995) Hepatitis A, B and C: Defining workers at risk. Viral Hepat 3 Google Scholar
Agarwal M, Malkan G, Bhave A, Vishwanathan C, Billa V, Dube S et al (1993) Antibody to hepatitis-C virus in multi-transfused thalassaemics--Indian experience. J Assoc Physicians India 41:195–197 [PubMed] [Google Scholar]
CAS
PubMed
Google Scholar
Ocak S, Kaya H, Cetin M, Gali E, Ozturk M (2006) Sero-prevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res 37:895–898 [PubMed] [Google Scholar]
Article
Google Scholar
Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G et al (2004) Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica 89:1179–1186 [PubMed] [Google Scholar]
PubMed
Google Scholar
Angelucci E, Pilo F (2008) Treatment of hepatitis C in patients with thalassemia. Haematologica 93:1121–1123 [PubMed] [Google Scholar]
Article
CAS
Google Scholar
Casu S, Balestrieri C, Figorilli F, Onali S, Serra G, Chessa L, Lai ME (2014) P1155 safety and efficacy of PEG IFnA 2a and ribavirin for treatment of hepatitis C in sardinian adult patients with thalassemia major, a single centre real life experience. J Hepat. 60(1):468. https://doi.org/10.1016/s0168-8278(14)61315-5
Article
Google Scholar
Paschos P, Vlachaki E, Pasvanti C, Sinakos E, Kalpaka A, Klonizakis P, Perifanis V (2011) Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience. Acta Haematol. 126(4):231–233. https://doi.org/10.1159/000330516
Article
PubMed
Google Scholar
Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N, for the Thalassemia Clinical Research Network (2008) Safety and efficacy of pegylated interferon alpha 2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 93(8):1247–1251. https://doi.org/10.3324/haematol.12352
Article
CAS
PubMed
Google Scholar
Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, Sharara AI (2005) Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 130(4):644–646. https://doi.org/10.1111/j.1365-2141.2005.05645.x
Article
CAS
PubMed
Google Scholar
Kamal SM, Fouly AH, Mohamed MK, Hochnikos BW, Lamont FT, Gohary IS, Koziel MJ, Afdhal NH, Sayed M, Rasenack JW (2006) 585 Peginterferon alpha 2b therapy with and without ribavirin in patients with thalassemia, a randomized study. J Hepatol. 44:217. https://doi.org/10.1016/s0168-8278(06)80585-4
Article
Google Scholar
lavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010; 17(4):236-244. doi: https://doi.org/10.1111/j.1365-2893.2009.01170.x.
European Association for the Study of the Liver (2018) Electronic address EEE. EASL recommendations on treatment of hepatitis C. J Hepatol http://doi.org/10.1016/j
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46(1):32–36. https://doi.org/10.1002/hep.21669
Article
CAS
Google Scholar
Alavian S, Tabatabaei S, Lankarani K (2010) Epidemiology of HCV Infection among Thalassemia Patients in Eastern Mediterranean Countries: a Quantitative Review of Literature. Iran. Red. Crescent. Med. 12(4):365–376
Google Scholar
Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, Fraquelli M, Paggi S, Conte D (2002) Age at infection affects the long term outcome of transfusion associated chronic hepatitis C. Blood. 99(12):4588–4591. https://doi.org/10.1182/blood-2001-12-0192
Article
CAS
PubMed
Google Scholar
Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A et al (2012) A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 91(9):1451–1458. https://doi.org/10.1007/s00277-012-1465-7
Article
PubMed
Google Scholar
Onali S, Maida I, Balestrieri C, Arcadu F, Urru E, Porcu D, Serra G, Flore G, Dore E, Satta C, Paolo Bitti P, Grazia Sanna M, Serusi L, Casale M, Conti M, Loi M, Figorilli F, Cristina Pasetto M, Babudieri S, Chessa L (2018) Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C. Hepat Mon. 18(1):e61453. https://doi.org/10.5812/hepatmon.61453
Article
CAS
Google Scholar
Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V. Treatment of chronic hepatitis C with direct-acting antivirals in patients with beta thalassaemia major and advanced liver disease. Br J Haematol. 2017; 178(1):130-136. doi: https://doi.org/10.1111/bjh.14640. [PubMed: 28439915].
Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, et al. Elbasvir, grazoprevir for patients with hepatitis c virus infection and inherited blood disorders: a phase III study. Hepatology. 2017; 66(3):736-745. doi: https://doi.org/10.1002/hep.29139. [PubMed: 28256747].
Biliotti E, Palazzo D, Serani M, Silvestri AM, Volpicelli L, Esvan R, Franchi C, Spaziante M, Sorrentino F, Taliani G Interferon free antiviral treatment of chronic hepatitis C in patients affected by beta-thalassemia major. Ann Hematol. 2017; 96(6):1043-1045. doi: https://doi.org/10.1007/s00277-017-2986-x. [PubMed: 28378040].
Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G (2017) Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 46(4):424–431. https://doi.org/10.1111/apt.14197
Article
CAS
PubMed
Google Scholar
European Association for the Study of the Liver. Electronic address EEE (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 66(1):153–194. https://doi.org/10.1016/j.jhep.2016.09.001
Article
Google Scholar
Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M (1996) Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am. J. Gastroenterol. 91(7):1367–1373
CAS
PubMed
Google Scholar